Indena S.p.A   Report issue

For profit Phase 2
Founded: Milan Italy (1924)
Status: No NME R&D (1924)

Organization Overview

First Clinical Trial
2011
NCT01375114
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Indena S.p.A

Active Ingredients

Drugs in Phase 2 Trials (4)

3-glycosyl-3-odemethylthiocolchicine (1 trial)

ginseng (1 trial)

samital (1 trial)

yinhsing (1 trial)

Drugs in Other Trials (3)

artichoke leaf extract (2 trials)

curcumin (1 trial)

quercetin (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Back Pain (Phase 2)

Carcinoma (Phase 2)

Carcinoma, Squamous Cell (Phase 2)

Fatigue (Phase 2)

Genomic Instability (Phase 2)

Low Back Pain (Phase 2)

Mucositis (Phase 2)

Squamous Cell Carcinoma of Head and Neck (Phase 2)

Stomatitis (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 8
  • # of Trial APIs: 7